Navigation Links
The MedZilla Report for January 2010 - Health Care Closes 2009 Strong, But Pharma Continues Shedding Jobs
Date:1/23/2010

As an extremely difficult year came to a close, the health care industry remained a bright spot in terms of employment growth. But that was offset by a rough ride for pharmaceuticals, which shed more than 60,000 jobs in 2009. If the actions of the larger pharmaceutical companies going into 2010 are any indication, the trouble isn't over just yet.

(Vocus) January 21, 2010 -- As one of the most difficult economic years in the past two decades came to a close, the health care industry remained one bright spot, adding another 22,000 jobs in December 2009, according to the United States Bureau of Labor Statistics. Additionally, the overall unemployment rate in the U.S. remained steady at 10 percent. However, December was a difficult month for the pharmaceutical industry, closing out a difficult year that saw the elimination of more than 60,000 pharmaceutical company jobs, according to outplacement consultants Challenger, Gray & Christmas.

Pharmaceutical company layoffs dominated that industry's news feeds in December, including many reports of job losses in the northeastern U.S. Smaller companies did announce layoffs in December -- such as Forest Labs, which was forced to let 84 workers go (newsday.com, 12/2/09) -- but the bigger names dominated the news as the year ended. Pfizer announced plans to cut 680 jobs in Pennsylvania, mostly from campuses acquired in their purchase of Wyeth (philly.com, 1/9/10), and further noted that they would have to eliminate a total of 20,000 jobs following the Wyeth purchase. Pfizer also received more bad news in December, announcing that they were halting a trial of a new lung cancer medication, due to its ineffectiveness in
'/>"/>

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. The MedZilla Report for November 2009 - Healthcare Employment Up, And No Major Bad News for Pharma, Either
2. The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close
3. The MedZilla Report for September 2009 - Care Grows Again in September and - Surprisingly - Pharma Sales Jobs Up Too
4. The MedZilla Report for August 2009 -- Health Care Grows Another 28,000 While Hospitals And Insurers Feel Painful Pinch
5. The MedZilla Report for July, 2009 - Health Care Creates 20,000 More Jobs As Economy Hits Insurers
6. The MedZilla Report: June 2009 Employment Outlook for Biotech/Pharma/Health
7. The MedZilla Report: May 2009 Employment Outlook for Biotech/Pharma/Health
8. The MedZilla Report: April 2009 Employment Outlook for Biotech/Pharma/Health
9. The MedZilla Report: March 2009 Employment Outlook for Biotech/Pharma/Health
10. The MedZilla Report: Febraury 2009 Employment Outlook for Biotech/Pharma/Health
11. The MedZilla Report: October 2008 Employment Outlook for Biotech/Pharma/Health
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
The MedZilla Report for January 2010 - Health Care Closes 2009 Strong, But Pharma Continues Shedding Jobs
(Date:5/17/2013)... The new Public-Private Partnership (PPP) in Photonics ... recent annual meeting drew praise from community leaders from ... called the action “a huge step forward … a ... innovation.” , The Board of Stakeholders voted to approve ... at its 29 April meeting in Brussels, which was ...
(Date:5/17/2013)... 17, 2013  Yongye International, Inc. (NASDAQ: ... manufacturer, and distributor of crop nutrient products in ... announced that, on May 16, 2013, the special committee ... "Board of Directors") was provided a letter (the "Letter") ... ) Limited ("Abax") to Full Alliance International Limited ...
(Date:5/17/2013)... 2013 The paradigm of ‘one drug, ... that can help predict the adverse and therapeutic effects ... Head of Computational Biology at the Genomics Laboratory, Covance, ... ensure high-quality genomics when used as part of the ... complex data sets to identify key clinical targets even ...
(Date:5/17/2013)... May 17, 2013 Tooth decay is an ... active signs of the disease. The World Health Organization says ... 100% of adults have cavities. What are the long-term effects ... showing a strong connection between the oral bacterial imbalance and ... disease so rampant, yet it is also 100% preventable? Answer: ...
Breaking Biology Technology:SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 3Yongye International Provides Update on Status of Proposed Go Private Offer 2Yongye International Provides Update on Status of Proposed Go Private Offer 3Yongye International Provides Update on Status of Proposed Go Private Offer 4Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3
... Schering-Plough,Corporation (NYSE: SGP ) today announced that ... the Peg-IFN (peginterferon alfa-2b),supplemental Biologics License Application (sBLA) ... the adjuvant treatment of patients with,Stage III melanoma. ... fall of 2007., The Priority Review designation ...
... Inc. (Nasdaq: ALXA ) announced today that ... 10th Annual BIO CEO & Investor,Conference on Monday, ... The presentation will be webcast from the ... presentation via the Web, please go to the,Investor ...
... Increase to Record Highs, BEDFORD, Mass., Jan. 31 ... technologies company specializing in,diagnostics, imaging systems and interventional devices ... its results for the,quarter ended December 29, 2007., ... revenues of $371.4 million. -- Merger with Cytyc ...
Cached Biology Technology:FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma 2FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma 3FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma 4FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma 5FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma 6Alexza's Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference 2Hologic Announces First Quarter Fiscal 2008 Operating Results 2Hologic Announces First Quarter Fiscal 2008 Operating Results 3Hologic Announces First Quarter Fiscal 2008 Operating Results 4Hologic Announces First Quarter Fiscal 2008 Operating Results 5Hologic Announces First Quarter Fiscal 2008 Operating Results 6Hologic Announces First Quarter Fiscal 2008 Operating Results 7Hologic Announces First Quarter Fiscal 2008 Operating Results 8Hologic Announces First Quarter Fiscal 2008 Operating Results 9Hologic Announces First Quarter Fiscal 2008 Operating Results 10Hologic Announces First Quarter Fiscal 2008 Operating Results 11Hologic Announces First Quarter Fiscal 2008 Operating Results 12Hologic Announces First Quarter Fiscal 2008 Operating Results 13Hologic Announces First Quarter Fiscal 2008 Operating Results 14Hologic Announces First Quarter Fiscal 2008 Operating Results 15
(Date:5/16/2013)... 2013 Reportlinker.com announces that a ... its catalogue: Global Biometric ... http://www.reportlinker.com/p01181929/Global-Biometric-Systems-Market-Forecast--Opportunities-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Security_Systems Lack ... such as photographs, passwords and PIN codes ... in last few years. Security threats such ...
(Date:5/15/2013)... moderating gout risk, new research reveals that vitamin C, ... (urate) levels to a clinically significant degree in patients ... combination with allopurinol, appears to have a weak effect ... to the results published in the American College of ... , Gout is an inflammatory arthritis that causes excruciating ...
(Date:5/15/2013)... clinical trial to date to examine the efficacy of ... other than breast and ovarian cancer, the oral drug ... and prostate cancers. Results of the study, led by ... University of Pennsylvania and Sheba Medical Center in Tel ... of Clinical Oncology,s annual meeting in Chicago in early ...
Breaking Biology News(10 mins):Global Biometric Systems Market Forecast & Opportunities, 2018 2Global Biometric Systems Market Forecast & Opportunities, 2018 3Global Biometric Systems Market Forecast & Opportunities, 2018 4Global Biometric Systems Market Forecast & Opportunities, 2018 5Global Biometric Systems Market Forecast & Opportunities, 2018 6Global Biometric Systems Market Forecast & Opportunities, 2018 7Vitamin C does not lower uric acid levels in gout patients 2PARP inhibitor shows activity in pancreatic, prostate cancers among patients carrying BRCA mutations 2
... Tuesday, Nov. 16, 2010 Tying in with this ... pre-conference workshops will debut at this year,s TERMIS-North America ... Fla. The TERMIS (Tissue Engineering & Regenerative ... the Wake Forest Institute for Regenerative Medicine, and chaired ...
... SAN DIEGO New research indicates that the ... About two percent of the population has a condition called ... are experienced at once. Although this condition is rare, the ... sometimes overlapping ways to help people interpret and understand their ...
... examining the distinct wave patterns formed from complex biochemical ... more effectively identified, says Zhengdong Cheng, associate professor in ... A&M University, who has developed a model that simulates ... which appear in the October issue of the journal ...
Cached Biology News:Regenerative medicine workshops to debut at TERMIS North America Annual Conference 2Hearing colors, seeing sounds: New research explores sensory overlap in the brain 2Research links damaged organs to change in biochemical wave patterns 2
...
Sterile detoxified 10% bovine serum albumin (BSA) in Iscoves MDM. This BSA has been selected to support the optimal colony growth of human hematopoietic progenitor cells in methylcellulose-based medi...
... ICP-MS system designed for flexibility and routine ... off-axis ion lens, true hyperbolic quadrupole and ... the widest range of sample types and ... includes as standard Agilents unique ShieldTorch System, ...
... it uses a deep-UV deuterium bulb, which provides ... a shutter (controlled via a TTL signal or ... DH-2000 Deuterium Tungsten Halogen Light Source combines the ... sources in a single optical path. The combined-spectrum ...
Biology Products: